NR4A1 and breast carcinoma: Given the heterogeneity of breast cancer phenotypes, for a randomized clinical trial to be informative it would need to be powered sufficiently to include adequate numbers of the different breast cancer phenotypes (e.g., hormone receptor types or HER2 expression levels).